Skip to main content
SpringerLink
Log in

Treatment of Kaposis Sarcoma

  • Chapter
HIV & HTLV-I Associated Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR,volume 104))

Abstract

Kaposi’s sarcoma (KS) is the most common malignancy associated with human immunodeficiency virus-1 (HIV) infection.’ During the early years of the acquired immunodeficiency syndrome (AIDS) epidemic, KS was the presenting manifestation of AIDS in 10%-15% of HIV-infected homosexual men and 1%-2% of HIV-infected individuals from other risk categories.2Over the past decade, the proportion of individuals presenting with KS as their AID S-defining illness has declined. Data from the Multicenter AIDS Cohort Study (MACS), an observational study of homosexual and bisexual men, demonstrate an increase in the incidence of KS as an AIDS-defining event in the early 1990s followed by a decline in incidence in 1996-1997.3KS as a secondary AIDS diagnosis rose from 23% in the mid-1980s, to 42% in the early 1990s, to 50% in 1996-1997.3In recent years, the overall incidence of KS has decreased. A population based cancer surveillance study in Washington state observed a decrease in the average number of KS cases from 118 between 1990 and 1995 to 76 in 1996 and 21 in 1997.4

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lyter DW, Bryant J, Tackeray R, et al. Incidence of human immunodeficiency virus related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 13 (10): 2540–2546, 1995.

    PubMed  CAS  Google Scholar 

  2. Centers for Disease Control: First 500,000 cases-United States, 1995. Morbid Mortal Weekly Rep 44:849–853, 1995.

    Google Scholar 

  3. Jacobson LP, et al. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individuals. The Second Natl AIDS Malignancy Conference (abstract) S5, 1998.

    Google Scholar 

  4. Wiggins CL, Aboulafia DM, Ryland LM, et al. Decline in HIV-associated Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) following the introduction of highly active antiretroviral therapy (HAART). The Third Natl AIDS Malignancy Conference (abstract) 21(1): A15, 1999.

    Google Scholar 

  5. Nichols CM, Fraitz CM, Hicks MJ. Treating Kaposi’s lesions in the HIV-infected patient. J Am Dent Assoc 124:78, 1993.

    PubMed  CAS  Google Scholar 

  6. Huang L, Schnapp LM, Goodman PC, et al. Presentation of Pulmonary Kaposi’s sarcoma (abstract PB 110) in Programs and Abstracts of the 10thInternational Conference on AIDS. 171, 1994.

    Google Scholar 

  7. Niedt GW, Schinella A. Acquired immunodeficiency syndrome clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 109:727–734, 1985.

    PubMed  CAS  Google Scholar 

  8. Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi’s sarcoma of internal organs. Cancer 75:1376–1385, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Meduri GU, Stover DE, Lee M, et al. Pulmonary Kaposi’s sarcoma in the acquired immune deficiency syndrome. Am J Med 81:11–18, 1986.

    Article  PubMed  CAS  Google Scholar 

  10. Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 105:1314, 1994.

    Article  PubMed  CAS  Google Scholar 

  11. Lee VW, Fuller JD, O’Brien MJ, et al. Pulmonary Kaposi’s sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning. Radiology 80:409, 1991.

    Google Scholar 

  12. Krown SE, Metroka C, Wernz JC, et al. Kaposi’s sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response and staging criteria. J Clin Oncol 7(9):1201–1207, 1989.

    PubMed  CAS  Google Scholar 

  13. Krown SE, Testa M, Huang J. AIDS-related Kaposi’s sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification: AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15(9):3085–3092, 1997.

    PubMed  CAS  Google Scholar 

  14. Barillari G, Gendelman R, Gallo RC, et al. The tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi’s sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 90:7941, 1993.

    Article  PubMed  CAS  Google Scholar 

  15. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946–954, 1997.

    PubMed  CAS  Google Scholar 

  16. Olsen SJ, Moore PS. Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) and the etiology of KS. in: Friedman H, Medveczky P, Bendinelli M, eds. Molecular immunology of herpesviruses. New York, NY: Plenum Publishing Corporation (in press).

    Google Scholar 

  17. Moore PS, Kingsley LA, Holmberg SP, Spira T, Gupta P, Hoover D, Parry JP, Conley LJ, Jaffe HW, Chang Y. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS 10:175–180, 1996.

    Article  PubMed  CAS  Google Scholar 

  18. Looney DJ, Wikthe W, Feigal E, et al. Relationship of HHV-8 peripheral blood mononuclear cell burden to immunodeficiency, opportunistic infections, response to therapy and stage of Kaposi’s sarcoma. lstNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A35, 1997 (abstr 75).

    Google Scholar 

  19. Quinlevan B, Ye D, Wehkie R, et al. Frequency of HHV-8 detection in peripheral blood cells in patients with Kaposi’s sarcoma. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 24).

    Google Scholar 

  20. Tamm M, Reichenberger F, McGandy C, Stalder A, Tietz A, Dalquen P, Perruchoud AP, Cathomas G Diagnosis of pulmonary Kaposi’s sarcoma by detection of human herpes virus 8 in bronchoalveolar lavage. Am J Respir Crit Care Med 157:458–63, 1997.

    Google Scholar 

  21. Feigal EG, Von Roenn JH, Justice K, et al. Kaposi’s sarcoma response criteria identified by the National Cancer Institute, food and Drug Administration and the AIDS Malignancy Consortium. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 24).

    Google Scholar 

  22. Volm MD, Wernz J. Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy. Proceedings of ASCO 16, 1997 (abstr 162).

    Google Scholar 

  23. Routy JP, Urbanek A, MacLeod J, et al. Significant regression of Kaposi’s sarcoma following initiation of an effective antiretroviral combination treatment. 1stNatl AIDS Malignancy Conference, Bethesda, MD. J Acq Imm Def Syn 14(4):A22, 1997 (abstr 23).

    Google Scholar 

  24. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer 31B(4):280–285, 1995.

    CAS  Google Scholar 

  25. Webster GF. Local therapy for mucocutaneous Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome. Dermatol Surg 21:205–208, 1995.

    PubMed  CAS  Google Scholar 

  26. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS associated Kaposi’s sarcoma. Int J Radiat Oncol 27:1057–1061, 1993.

    Article  CAS  Google Scholar 

  27. Piedbois P, Frikha H, Martin L, et al. Radiotherapy in the management of epidemic Kaposi’s sarcoma. Int J Radiat Oncol 30(5):1207–1211, 1994.

    Article  CAS  Google Scholar 

  28. Swift PS. Radiation therapy in the management of HIV-related KS. Hematology/Oncology Clinics of North America 10(5): 1069–1080, 1996.

    Article  PubMed  CAS  Google Scholar 

  29. Conant M. Topical Alitretinoin gel as treatment for cutaneous lesions of patients with AIDS-related Kaposi’s sarcoma: Results of two multi-center, double-blind, vehicle-controlled trials. 6thConf on Retroviruses and Opportunistic Infections, Chicago, IL, 1999 (abstr 205).

    Google Scholar 

  30. Ligand Pharmaceuticals Inc. Manufacturer’s package insert. February 1999.

    Google Scholar 

  31. Volberding PA, Mitsuyasu RT, Golando JP, et al. Treatment of Kaposi’s sarcoma with interferon alfa-2b (Intron A). Cancer 59:620–625, 1987.

    Article  PubMed  CAS  Google Scholar 

  32. Mauss S, Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon alpha-2b and zidovudine in early stage AIDS-associated Kaposi’s sarcoma. J Acq Imm Def Syn 10:157–162, 1995.

    CAS  Google Scholar 

  33. Fischl MA, Finkelstein DM, He W, et al. A phase II study of recombinant human interferon alpha-2b and zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acq Imm Def 11:379–385, 1996.

    CAS  Google Scholar 

  34. Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alpha with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study. J Clin Oncol 16(5):1736–1742, 1998.

    PubMed  CAS  Google Scholar 

  35. Paredes J, Kahn JO, Tong WP, et al. Weekly oral etoposide in patients with Kaposi’s sarcoma associated with human immunodeficiency virus infection: A phase 1 multicenter trial of the AIDS Clinical Trials Group. J Acq Imm Def Syn 9:138–144, 1995.

    CAS  Google Scholar 

  36. Volberding PA, Abrams DI, Conant M, et al. Vinblastine therapy for Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Int Med 103:335–338, 1985.

    PubMed  CAS  Google Scholar 

  37. Mintzer DM, Real FX, Jovino L, et al. Treatment of Kaposi’s sarcoma and thrombocytopenia with vincristine in patients with acquired immune deficiency syndrome. Ann Int Med 102:200–202, 1985.

    PubMed  CAS  Google Scholar 

  38. Caumes E, Guermonprez G, Katlama C, et al. AIDS-associated mucocutaneous Kaposi’s sarcoma treated with bleomycin. AIDS 6:1483–1487, 1992.

    Article  PubMed  CAS  Google Scholar 

  39. Remick SC, Reddy M, Herman D, et al. Continuous infusion bleomycin in AIDS-related Kaposi’s sarcoma. J Clin Oncol 12:1130–1136, 1994.

    PubMed  CAS  Google Scholar 

  40. Fischl MA, Krown SE, O’Boyle KP, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. J Acq Imm Def Syn 6:259–264, 1993.

    CAS  Google Scholar 

  41. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 346:26–28, 1995.

    Article  PubMed  CAS  Google Scholar 

  42. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 17:1876–1883, 1997.

    Google Scholar 

  43. Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acq Imm Def Syn 7:463–468, 1994.

    CAS  Google Scholar 

  44. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 13:914–920, 1995.

    PubMed  CAS  Google Scholar 

  45. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma. Lancet 341:1242–1243, 1993.

    Article  PubMed  CAS  Google Scholar 

  46. Tulpule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s sarcoma. J Clin Oncol 16: 3369–374, 1998.

    Google Scholar 

  47. Gill PS, Rarick MU, Espina B, et al. Advanced acquired immunodeficiency syndrome-related Kaposi’s sarcoma: Results of pilot studies using combination chemotherapy. Cancer 65:1074–1078, 1990.

    Article  PubMed  CAS  Google Scholar 

  48. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi’s sarcoma. J Clin Oncol 14:2353–2364, 1996.

    PubMed  CAS  Google Scholar 

  49. Gill PS, Ravick MU, Bernstein-Singer M, et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Ann J Clin Oncol 13:315319, 1990.

    Google Scholar 

  50. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi’s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 70:1121–1122, 1986.

    PubMed  CAS  Google Scholar 

  51. Laubenstein LJ, Krigel RL, Odajnyk CM, et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 2:1115–1120, 1984.

    PubMed  CAS  Google Scholar 

  52. Gompels MM, Hill A, Jenkins P, et al. Kaposi’s sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 6:1175–1180, 1992.

    Article  PubMed  CAS  Google Scholar 

  53. Sloand E, Kumar PN, Pierce PF. Chemotherapy for patients with pulmonary Kaposi’s sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. South Med J 86:1219–1224, 1993.

    Article  PubMed  CAS  Google Scholar 

  54. Bakker PJM, Danner SA, Napel CH, et al. Treatment of poor prognosis epidemic Kaposi’s sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF). Eur J Cancer 31A:188–192, 1995.

    Article  PubMed  CAS  Google Scholar 

  55. Northfelt DW, Dezube B, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445–2451, 1998.

    PubMed  CAS  Google Scholar 

  56. Stewart JSW, Jabonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 16:683–691, 1998.

    PubMed  CAS  Google Scholar 

  57. Mitsuyasu R, Von Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi’s sarcoma (AIDS-KS): AIDS Clinical Trials Group (ACTG) protocol 286 (abstract) Proc Am Soc Clin Oncol 16:55a, 1997.

    Google Scholar 

  58. Gabizon A, Catane R, Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992, 1994.

    PubMed  CAS  Google Scholar 

  59. Ross M, Gill PS, Espina BM, et al. Liposomal daunorubicin (DaunoXome) in the treatment of advanced AIDS-related Kaposi’s sarcoma: Results of a phase II study (abstract PoB 3123). Int Conf AIDS 8:B107, 1992.

    Google Scholar 

  60. Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol (abst 843) 15:303, 1996.

    Google Scholar 

  61. Gordon KB, Tajuddin A, Guitart J, et al. Hand foot syndrome associated with liposome encapsulated doxorubicin therapy. Cancer 75(8):2169–2173, 1995.

    Article  PubMed  CAS  Google Scholar 

  62. Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, et al. Fumagillin analog (TNP-470) in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trials Group trial. J Clin Oncol 16:1444–1449, 1998.

    PubMed  CAS  Google Scholar 

  63. Fife K, Howard MR, Gracie F, Phillips RH, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre. Intl J STD & AIDS 9:751–755, 1998.

    Article  CAS  Google Scholar 

  64. Gelsby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi’s sarcoma: Data from the Multicenter AIDS Cohort Study. AIDS 10:1101–1105, 1996.

    Google Scholar 

  65. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. J Clin Investig 99:2082–2086, 1997.

    Article  Google Scholar 

  66. Kedes DH, Ganem D: Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Investig 99:2082–2086, 1997.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, USA

    Jamie H. Von Roenn & Mary Cianfrocca

Authors
  1. Jamie H. Von Roenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Cianfrocca
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Albert Einstein College of Medicine, Montefiore Medical Center, New York, USA

    Joseph A. Sparano MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Von Roenn, J.H., Cianfrocca, M. (2001). Treatment of Kaposis Sarcoma. In: Sparano, J.A. (eds) HIV & HTLV-I Associated Malignancies. Cancer Treatment and Research, vol 104. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1601-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1601-9_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5635-6

  • Online ISBN: 978-1-4615-1601-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation